Latest Regulatory Scrutiny News

TerraCom Limited has reached a significant settlement with ASIC to resolve whistleblower-related civil proceedings, agreeing to pay $8.5 million pending Federal Court approval.

Wellnex Life Limited’s shares have been suspended from trading on the ASX pending a response to regulatory queries, stirring investor uncertainty.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.

Yowie Group Ltd has firmly rejected the validity of director removal and nomination notices purportedly from Keybridge Capital, while confirming its status as Keybridge’s largest creditor with over $6.6 million owed. The company also detailed a recent share placement amid ongoing regulatory scrutiny.

The ASX has formally queried Bougainville Copper Limited following an unexpected surge in its share price and trading volume, seeking clarity on any undisclosed information that might explain the market activity.

Mount Burgess Mining NL has had its trading suspension lifted following a court ruling validating a recent cleansing notice, allowing shares to re-enter the market from 20 May 2025.

NSX Limited has entered a Scheme Implementation Deed with CNSX Markets Inc. for a full acquisition at a 59% premium, subject to shareholder and regulatory approvals. The deal aims to strengthen NSX’s market position and expand its product offerings.

QBE Insurance Group has priced a AUD 600 million subordinated notes issuance, strengthening its capital base under APRA regulations with notes maturing in 2036.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

An application to the Takeovers Panel challenges Pact Group Holdings’ planned ASX delisting, citing concerns over shareholder disadvantage and selective disclosure.

Macquarie Bank Limited reported an 18% rise in net profit for FY2025, driven by growth in its retail banking segment despite margin pressures, while its commodities business faced subdued markets. The bank maintained strong capital ratios and advanced its risk and technology frameworks amid regulatory scrutiny.